BRAF and beyond: Tailoring strategies for the individual melanoma patient
Until recently, options for therapy in metastatic melanoma were limited. The understanding of immune check-point blockade and the discovery of molecular pathways involving driver mutations like BRAF has transformed the therapeutic landscape in this disease. Ipilimumab was the first drug shown to imp...
Main Authors: | Anthony Jarkowski, Nikhil I Khushalani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Journal of Carcinogenesis |
Subjects: | |
Online Access: | http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2014;volume=13;issue=1;spage=1;epage=1;aulast=Jarkowski |
Similar Items
-
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
by: Ernesto Rossi, et al.
Published: (2019-04-01) -
“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
by: Mattia Garutti, et al.
Published: (2020-07-01) -
Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
by: Raphael Reinhard, MD, et al.
Published: (2018-03-01) -
Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
by: Patrick A. Ott, et al.
Published: (2013-10-01) -
Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
by: Yukiko Kiniwa, et al.
Published: (2021-03-01)